Patents by Inventor Mark S. Chambers

Mark S. Chambers has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230028381
    Abstract: Systems and methods for facilitating an enterprise user to obtain an answer to a user question within an enterprise based on an enterprise knowledge graph are provided. In particular, an enterprise server may receive the user question from the enterprise user, determine a suggested topic associated with the user question based on the enterprise knowledge graph by transforming the user question into a semantic representation to identify a plurality of similar entities within the enterprise knowledge graph, and determine whether a relevant question-and-answer (Q&A) pair linked to the suggested topic exists based on the enterprise knowledge graph. In response to a determination that the relevant Q&A pair does not exist, the enterprise server may determine a predicted answer to the user question and update the enterprise knowledge graph.
    Type: Application
    Filed: July 20, 2021
    Publication date: January 26, 2023
    Applicant: Microsoft Technology Licensing, LLC
    Inventors: Dmitriy MEYERZON, Victor POZNANSKI, Nikita VORONKOV, Ryen W. WHITE, Eric GRADEL, Mark J. ENCARNACIÓN, Kerem YUCETURK, Michael GAMON, Nirupama CHANDRASEKARAN, Silviu-Petru CUCERZAN, Keith Richard CHAMBERS, John William BACUS, Aaron Lee HALFAKER, James S. WOFFINDEN-LUEY, Youngji KIM
  • Publication number: 20190046515
    Abstract: The present invention is related to amino thiazole derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
    Type: Application
    Filed: October 16, 2018
    Publication date: February 14, 2019
    Inventors: PETER MACHIN, ANDREW SHARPE, CHRISTOPHER JAMES LOCK, MARK S. CHAMBERS, ALASTAIR HODGES, VIVIENNE ALLEN, JOHN M. ELLARD
  • Patent number: 10130619
    Abstract: The present invention is related to amino thiazole derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
    Type: Grant
    Filed: December 16, 2015
    Date of Patent: November 20, 2018
    Assignee: GENKYOTEX SUISSE SA
    Inventors: Peter Machin, Andrew Sharpe, Christopher James Lock, Mark S. Chambers, Alastair Hodges, Vivienne Allen, John M. Ellard
  • Publication number: 20170348296
    Abstract: The present invention is related to amino thiazole derivatives of Formula (I), pharmaceutical composition thereof and to their use for the treatment and/or prophylaxis of disorders or conditions related to Nicotinamide adenine dinucleotide phosphate oxidase (NADPH Oxidase).
    Type: Application
    Filed: December 16, 2015
    Publication date: December 7, 2017
    Inventors: PETER MACHIN, ANDREW SHARPE, CHRISTOPHER JAMES LOCK, MARK S. CHAMBERS, ALASTAIR HODGES, VIVIENNE ALLEN, JOHN M. ELLARD
  • Patent number: 5637699
    Abstract: Substituted heterocycles of the general structural formula: ##STR1## are tachykinin receptor antagonists useful in the treatment of inflammatory diseases, pain or migraine, asthma and emesis, and calcium channel blockers useful in the treatment of cardiovascular conditions such as angina, hypertension or ischemia.
    Type: Grant
    Filed: May 22, 1995
    Date of Patent: June 10, 1997
    Assignee: Merck & Co., Inc.
    Inventors: Conrad P. Dorn, Jeffrey J. Hale, Paul E. Finke, Malcolm MacCoss, Sander G. Mills, Shrenik K. Shah, Mark S. Chambers, Timothy Harrison, Tamara Ladduwahetty, Brian J. Williams
  • Patent number: 5618812
    Abstract: Compounds of Formula (I), and salts and prodrugs thereof, wherein R.sup.1 represents H, optionally substituted C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 is NHR.sup.12 or (CH.sub.2).sub.s R.sup.13 where 5 is 0, 1 or 2; R.sup.3 represents C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 and R.sup.5 are H, C.sub.1-12 alkyl optionally substituted by NR.sup.9 R.sup.9' or an azacyclic or azabicyclic group, optionally substituted C.sub.4-9 cycloalkyl, C.sub.4-9 cycloalkyl C.sub.1-4 alkyl, aryl, arylC.sub.1-6 alkyl or azacyclic or azabicyclic groups, or R.sup.4 and R.sup.5 together form the residue of an optionally substituted azacyclic or azabicyclic ring system; x is 0, 1, 2 or 3; R.sup.12 is optionally substituted phenyl or pyridyl; R.sup.13 represents a group (A) wherein R.sup.14 is H or C.sub.1-6 alkyl; R.sup.15 is H, C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; and the dotted line is an optional covalent bond; are CCK and/or gastrin antagonists useful in therapy.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: April 8, 1997
    Assignee: Merck Sharp & Dohme, Ltd.
    Inventors: Jose L. Castro Pineiro, William R. Carling, Mark S. Chambers, Stephen R. Fletcher, Sarah C. Hobbs, Victor G. Matassa, Kevin W. Moore, Graham A. Showell, Michael G. Russell
  • Patent number: 5604240
    Abstract: A class of substituted pyrrolo[2,3-c]pyridine derivatives are selective agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
    Type: Grant
    Filed: November 16, 1995
    Date of Patent: February 18, 1997
    Assignee: Merck, Sharp & Dohme, Ltd.
    Inventors: Mark S. Chambers, Victor G. Matassa
  • Patent number: 5597915
    Abstract: Compounds of Formula (I), and salts and prodrugs thereof wherein: R.sup.1 is H, certain optionally substituted C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 represents a group (a) wherein X is O, S or NR.sup.8 where R.sup.8 is H or C.sub.1-4 alkyl; one of Z and Y is C.dbd.O and the other is O, S or NR.sup.9, where R.sup.9 is H or C.sub.1-4 alkyl; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ; R.sup.4 is C.sub.3-10 cycloalkyl; n is 0, 1, 2 or 3, and are CCK and/or gastrin antagonists, which compounds and compositions thereof are useful in therapy.
    Type: Grant
    Filed: September 15, 1994
    Date of Patent: January 28, 1997
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark S. Chambers, Stephen R. Fletcher, Victor G. Matassa, Mark G. Bock
  • Patent number: 5556969
    Abstract: Compounds of the formula (I): ##STR1## wherein R.sub.1 is hydrogen or specified optionally substituted alkyl, R.sup.2 is specified optionally substituted phenyl or pyridyl, x is 0, 1, 2 or 3, R.sup.3 is a specified alkyl, halo or amino and R.sup.4 is specified cycoalkyl or bicycloalkyl; and salts and prodrugs thereof, are useful as antagonists of cholecystokin and gastrin receptors.
    Type: Grant
    Filed: June 29, 1995
    Date of Patent: September 17, 1996
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark S. Chambers, Stephen R. Fletcher
  • Patent number: 5521175
    Abstract: Compounds of Formula (I), and salts and prodrugs thereof, wherein R.sup.1 represents C.sub.1-6 alkyl or C.sub.3-7 cycloalkyl; R.sup.2 optionally substituted phenyl or R.sup.2 represents a group (A) where W is CH.sub.2 or NR.sup.10, and W.sup.1 is CH.sub.2, or W and W.sup.1 each represent 0; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.13 R.sup.14 ; R.sup.4 is H, C.sub.1-4 alkyl, optionally substituted phenyl or optionally substituted benzyl; R.sup.5, R.sup.6, R.sup.7 and R.sup.8 are H or C.sub.1-4 alkyl; or any two of R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 together form a chain (CH.sub.2).sub.t, and any other two of R.sup.4, R.sup.5, R.sup.6, R.sup.7 and R.sup.8 optionally form a chain (CH.sub.2).sub.s where s and t are independently 1, 2 or 3; m is 2, 3, 4, 5, 6, 7, 8 or 9; n is 0, 1, 2, 3 or 4; and x is 0, 1, 2 or 3; are CCK and/or gastrin antagonists useful in therapy.
    Type: Grant
    Filed: January 26, 1995
    Date of Patent: May 28, 1996
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Jose L. Castro Pineiro, Mark S. Chambers, Victor G. Matassa
  • Patent number: 5451582
    Abstract: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein: R.sup.1 is H, certain optionally substituted C.sub.1.6 alkyl, or C.sub.3-7 cycloalkyl;R.sup.2 is (CH.sub.2).sub.q -tetrazolyl optionally substituted in the tetrazole ring by C.sub.1-4 alkyl, (CH.sub.2).sub.q -imidazolyl (where q is 0, 1, 2 or 3), CONHSO.sub.2 R.sup.9, SO.sub.2 NHCOR.sup.9 (where R.sup.9 is C.sub.1-6 alkyl, optionally substituted aryl or trifluoromethyl). SO.sub.2 NHR.sup.10 (where R.sup.10 is a nitrogen containing heterocycle), cyclopropyl or (CH.sub.2), CO.sub.2 H, where n is 1 or 2;R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ;R.sup.4 is C.sub.1-7 straight or branched chain alkyl; andx is 0, 1, 2 or 3;are CCK and/or gastrin receptor antagonists. They and compositions thereof are useful in therapy.
    Type: Grant
    Filed: February 12, 1993
    Date of Patent: September 19, 1995
    Assignee: Merck Sharp & Dohme Ltd.
    Inventors: Mark S. Chambers, Victor G. Matassa, Stephen R. Fletcher
  • Patent number: 5410049
    Abstract: Compounds of formula (I), and salts and prodrugs thereof ##STR1## wherein: R.sup.1 is H, certain optionally substituted C.sub.1-6 alkyl, or C.sub.3-7 cyclocalkyl;R.sup.2 represents a group ##STR2## wherein X is O, S or NR.sup.8 where R.sup.8 is H or C.sub.1-4 alkyl; R.sup.3 is C.sub.1-6 alkyl, halo or NR.sup.6 R.sup.7 ;R.sup.4 is C.sub.1-7 alkyl, C.sub.3-7 cycloalkyl, C.sub.4-7 cycloalkylalkyl or optionally substituted aryl;n is 0, 1, 2 or 3; are CCK and/or gastrin receptor antagonists. They and compositions thereof are useful in therapy.
    Type: Grant
    Filed: December 17, 1992
    Date of Patent: April 25, 1995
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventor: Mark S. Chambers
  • Patent number: 5360802
    Abstract: This invention relates to benzodiazepine compounds which are useful as antagonists of cholecystokinin and gastrin.
    Type: Grant
    Filed: November 13, 1992
    Date of Patent: November 1, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Mark S. Chambers, Victor G. Matassa, Stephen R. Fletcher
  • Patent number: 5324733
    Abstract: A class of spirocyclic piperidine derivatives are selective ligands at sigma recognition sites and are therefore useful in the treatment and/or prevention of psychiatric disorders. The claimed compounds are of the formula ##STR1## wherein, A and B are hydrogen, Q is a bond, R.sup.11, R.sup.12, and R.sup.13 are as defined in the specification.
    Type: Grant
    Filed: April 22, 1993
    Date of Patent: June 28, 1994
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: David C. Billington, Mark S. Chambers
  • Patent number: 5219860
    Abstract: A class of spirocyclic piperidine derivatives are selective ligands at sigma recognition sites and are therefore useful in the treatment and/or prevention of psychiatric disorders.
    Type: Grant
    Filed: March 1, 1991
    Date of Patent: June 15, 1993
    Assignee: Merck Sharp & Dohme Limited
    Inventors: Mark S. Chambers, David C. Billington
  • Patent number: 5208248
    Abstract: A class of indazole-substituted five-membered heteroaromatic compounds are specific agonists of 5-HT.sub.1 -like receptors and are therefore useful in the treatment of clinical conditions, in particular migraine and associated disorders, for which a selective agonist of these receptors is indicated.
    Type: Grant
    Filed: July 16, 1991
    Date of Patent: May 4, 1993
    Assignee: Merck Sharpe & Dohme, Ltd.
    Inventors: Raymond Baker, Mark S. Chambers, Leslie J. Street